FrancophonIA/ELRC3.0 huggingface dataset:
English: The efficacy of adalimumab was assessed in a randomised, double-blind, controlled study of 114 paediatric patients from 4 years of age with severe chronic plaque psoriasis (as defined by a PGA ≥ 4 or > 20% BSA involvement or > 10% BSA involvement with very thick lesions or PASI ≥ 20 or ≥ 10 with clinically relevant facial, genital, or hand/foot involvement) who were inadequately controlled with topical therapy and heliotherapy or phototherapy.
Croatian: Djelotvornost adalimumaba ocjenjivala se u randomiziranom, dvostruko slijepom, kontroliranom ispitivanju provedenom u 114 pedijatrijskih bolesnika u dobi od 4 ili više godina s teškom kroničnom plak psorijazom (koja se definirala kao PGA rezultat od ≥ 4 ili zahvaćenost površine tijela od > 20% ili zahvaćenost površine tijela od > 10% s vrlo debelim lezijama ili PASI rezultat od ≥ 20 ili ≥ 10 uz klinički značajnu zahvaćenost lica, genitalija ili šaka/stopala) u kojih bolest nije bila dovoljno dobro kontrolirana topikalnom terapijom i helioterapijom ili fototerapijom.
English: AMGEVITA is injected under the skin (subcutaneous use).
Croatian: AMGEVITA se ubrizgava pod kožu (supkutana primjena).
English: ACR responses in placebo-controlled trials (percent of patients)
Croatian: ACR odgovori u ispitivanjima kontroliranim placebom (postotak bolesnika)
English: In the controlled portions of adalimumab clinical trials of TNF-antagonists, more cases of malignancies including lymphoma have been observed among patients receiving a TNF-antagonist compared with control patients.
Croatian: U kontroliranim dijelovima adalimumab kliničkih ispitivanja antagonista TNF-a zabilježeno je više slučajeva zloćudnih bolesti, uključujući i limfome, u bolesnika liječenih antagonistima TNF-a nego u kontrolnoj skupini.
English: The safety and efficacy of adalimumab were assessed in a multicentre, randomised, double-blind, parallel-group study in 171 children (4-17 years old) with polyarticular JIA.
Croatian: Sigurnost i djelotvornost primjene adalimumaba ocijenjena je u multicentričnom, randomiziranom, dvostruko-slijepom ispitivanju s paralelnim skupinama koje je uključivalo 171 dijete (u dobi od 4-17 godina) s poliartikularnim JIA.
English: Used plunger rod Finger flange
Croatian: Upotrijebljeni klip Hvatište za prste
English: D. Prepare and clean your injection site(s).
Croatian: Pripremite i očistite područje(a) injiciranja.
English: Based on the observed data approach, 222 (80.4%) were in quiescence (no active inflammatory lesions, AC cell grade ≤ 0.5+, VH grade ≤ 0.5+) with a concomitant steroid dose ≤ 7.5 mg per day, and 184 (66.7%) were in steroid-free quiescence.
Croatian: Prema pristupu utemeljenom na opaženim podacima, u 222 (80,4%) bolesnika bolest je bila u mirovanju (bez aktivnih upalnih lezija, stupanj prema broju stanica u prednjoj očnoj komori ≤ 0,5+, stupanj prema zamućenju staklovine ≤ 0,5+) uz istodobnu primjenu steroida u dozi od ≤ 7,5 mg na dan, dok je u njih 184 (66,7%) bolest bila u mirovanju bez primjene steroida.
English: In the open-label lead in phase (OL LI) patients were stratified into two groups, MTX (methotrexate)-treated or non-MTX
Croatian: U otvorenoj uvodnoj fazi ispitivanja bolesnici su podijeljeni u dvije skupine, jedna koja je uzimala metotreksat (označena s MTX) i ona koja nije (označena s ne- MTX).
English: Neurologic evaluation should be performed in patients with non-infectious intermediate uveitis prior to the initiation of AMGEVITA therapy and regularly during treatment to assess for pre-existing or developing central demyelinating disorders.
Croatian: U bolesnika s neinfektivnim intermedijarnim uveitisom treba provesti neurološku procjenu prije početka liječenja lijekom AMGEVITA i redovito tijekom liječenja kako bi se utvrdili otprije postojeći ili novorazvijeni demijelinizirajući poremećaji središnjeg živčanog sustava.
English: If you have mild heart failure and you are being treated with AMGEVITA, your heart failure status must be closely monitored by your doctor.
Croatian: • Bolujete li od blagog zatajenja srca, a liječite se lijekom AMGEVITA, liječnik mora pomno nadzirati status zatajenja srca.
English: RA study IIa**
Croatian: Ispitivanje RA IIa**
English: The safety and efficacy of adalimumab were assessed in two randomised, double-blind placebocontrolled studies in patients with non-radiographic axial spondyloarthritis (nr-axSpA).
Croatian: Sigurnost i djelotvornost adalimumaba bila je ispitana u dva randomizirana, dvostruko slijepa placebom kontrolirana ispitivanja u bolesnika s ne-radiografskim aksijalnim spondiloartritisom (nr-axSpA).
English: There are no clinical trials with adalimumab in adolescent patients with HS.
Croatian: Nisu provedena klinička ispitivanja s adalimumabom u adolescentnih bolesnika s gnojnim hidradenitisom.
English: Coagulation and bleeding disorders (including activated partial thromboplastin time prolonged), Autoantibody test positive (including double stranded DNA antibody),
Croatian: često poremećaji koagulacije i krvarenja (uključujući produljenje aktiviranog parcijalnog tromboplastinskog vremena), pozitivan nalaz testa na autoprotutijela (uključujući protutijela na dvolančanu DNK), povišena laktat dehidrogenaza u krvi
English: During the controlled portions of pivotal adalimumab trials in adults of at least 12 weeks in duration in patients with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn's disease, ulcerative colitis and uveitis, malignancies, other than lymphoma and non-melanoma skin cancer, were observed at a rate (95% confidence interval) of 6.8 (4.4, 10.5) per 1,000 patient-years among 5,291 adalimumab-treated patients versus a rate of 6.3 (3.4, 11.8) per 1,000 patient-years among 3,444 control patients (median duration of treatment was 4.0 months for adalimumab and 3.8 months for control-treated patients).
Croatian: U kontroliranim dijelovima pivotalnih ispitivanja terapije adalimumabom koja su trajala barem 12 tjedana u odraslih bolesnika s umjerenim do teškim aktivnim reumatoidnim artritisom, ankilozantnim spondilitisom, aksijalnim spondiloartritisom bez radiološkog dokaza AS-a, psorijatičnim artritisom, psorijazom, gnojnim hidradenitisom, Crohnovom bolešću, ulceroznim kolitisom i uveitisom, primijećene su zloćudne bolesti, isključujući limfome i nemelanomske tumore kože, u stopi od 6,8 (4,4; 10,5) na 1000 bolesnik-godina (interval pouzdanosti 95%) u 5291 bolesnika liječenog adalimumabom, naspram 6,3 (3,4; 11,8) na 1000 bolesnik-godina u 3444 bolesnika iz kontrolne skupine (medijan trajanja terapije bio je 4,0 mjeseci u bolesnika liječenih adalimumabom i 3,8 mjeseci u kontrolnoj skupini bolesnika).
English: Amongst those who responded at week 16 (n = 144), the paediatric ACR 30/50/70/90 responses were maintained for up to six years in the OLE phase in patients who received adalimumab throughout the study.
Croatian: Među bolesnicima koji su imali klinički odgovor u 16. tjednu (n = 144), pedijatrijski odgovori ACR 30/50/70/90 održali su se i do šest godina u otvorenom produžetku ispitivanja u bolesnika koji su uzimali adalimumab tijekom cijeloga ispitivanja.
English: Endoscopic studies in intestinal mucosa have shown evidence of mucosal healing in adalimumabtreated patients.
Croatian: Endoskopska ispitivanja intestinalne mukoze pokazala su znakove zacjeljivanja sluznice u bolesnika liječenih adalimumabom.
English: With the needle cap off, insert the syringe into your skin at 45 to 90 degrees.
Croatian: Uvedite iglu, s koje je uklonjen zatvarač, u kožu pod kutom od 45 do 90
English: Part of the AMGEVITA pre-filled syringe may be broken even if you cannot see the break.
Croatian: Dio AMGEVITA napunjene brizgalice može biti oštećen iako možda ne vidite oštećenje.
English: If you do not respond well enough to these medicines, you will be given AMGEVITA to reduce the signs and symptoms of your disease.
Croatian: Ako na njih ne odgovorite dovoljno dobro, dobit ćete lijek AMGEVITA kako bi se smanjili simptomi i znakovi Vaše bolesti.
English: Following 52 weeks and 104 weeks of treatment, the percentage of patients without progression (change from baseline in modified Total Sharp Score ≤ 0.5) was significantly higher with adalimumab/methotrexate combination therapy (63.8% and 61.2% respectively) compared to methotrexate monotherapy (37.4% and 33.5% respectively, p < 0.001) and adalimumab monotherapy (50.7%, p < 0.002 and 44.5%, p < 0.001 respectively).
Croatian: Nakon 52 i 104 tjedna liječenja, postotak bolesnika bez progresije bolesti (promjena ukupnog zbroja bodova prema Sharpu ≤ 0,5) bio je značajno veći u skupini liječenoj kombinacijom adalimumaba i metotreksata (63,8% odnosno 61,2%) u usporedbi sa skupinom koja je dobivala monoterapiju metotreksatom (37,4% odnosno 33,5%, p < 0,001) i monoterapiju adalimumabom (50,7%, p < 0,002 odnosno 44,5%, p < 0,001).
English: 0.8 mL of solution.
Croatian: 0,8 ml
English: Important: Throw the needle cap into the sharps disposal container provided.
Croatian: Važno: Odložite zatvarač igle u spremnik za odlaganje oštrih predmeta.
English: In paediatric uveitis, there is no experience in the treatment with AMGEVITA without concomitant treatment with methotrexate.
Croatian: Kod uveitisa u djece, nema iskustva s liječenjem lijekom AMGEVITA bez istodobnog liječenja metotreksatom.
English: • Adults with non-infectious uveitis with inflammation affecting the back of the eye.
Croatian: • odraslih osoba s nezaraznim uveitisom kod kojega upala zahvaća stražnji dio oka
English: The mean trough concentrations were maintained in patients who continued to receive adalimumab treatment every other week for 52 weeks.
Croatian: Srednje vrijednosti najniže koncentracije održale su se u bolesnika koji su nastavili primati adalimumab svaki drugi tjedan kroz 52 tjedna.
English: Side effects may occur at least up to 4 months after the last AMGEVITA injection.
Croatian: Nuspojave se mogu javiti barem još 4 mjeseca nakon ubrizgavanja zadnje doze lijeka AMGEVITA.
English: RA study IIIa**
Croatian: Ispitivanje RA IIIa**
English: The safety and efficacy of adalimumab were also studied in adult patients with moderate to severe chronic plaque psoriasis with concomitant hand and/or foot psoriasis who were candidates for systemic therapy in a randomised double-blind study (psoriasis study III).
Croatian: Sigurnost i djelotvornost adalimumaba također se ispitivala u odraslih bolesnika s umjerenom do teškom kroničnom plak psorijazom i istodobnom psorijazom šaka i/ili stopala koji su bili kandidati za sistemsku terapiju u randomiziranom, dvostruko slijepom ispitivanju (Psoriasis Study III).
English: Table 29.
Croatian: Tablica 29.
English: AMGEVITA is contraindicated in moderate to severe heart failure (see section 4.3).
Croatian: Primjena lijeka AMGEVITA je kontraindicirana u bolesnika s umjerenim do teškim zatajenjem srca (vidjeti dio 4.3).
English: It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating AMGEVITA therapy.
Croatian: Preporučuje se da se pedijatrijske bolesnike, ako je moguće, cijepi u skladu sa svim važećim smjernicama za cijepljenje prije započinjanja liječenja lijekom AMGEVITA.
English: AMGEVITA is a biosimilar medicinal product.
Croatian: AMGEVITA je biosličan lijek.
English: Thirty-three (18%) patients were treated concomitantly with disease-modifying anti-rheumatic drugs, and 146 (79%) patients with NSAIDs at baseline.
Croatian: Na početku je 33 bolesnika (18%) istodobno bilo liječeno antireumatskim lijekovima koji modificiraju tijek bolesti, a 146 (79%) NSAIL-ovima.
English: Hepatosplenic T-cell lymphoma1), Merkel cell carcinoma (neuroendocrine carcinoma of the skin)1)
Croatian: rijetko leukemija1) nepoznato hepatosplenični T-stanični limfom1) karcinom Merkelovih stanica (neuroendokrini karcinom kože)1)
English: Patients received adalimumab 0.8 mg/kg every other week (up to 40 mg), 0.4 mg/kg every other week (up to 20 mg), or methotrexate 0.1-0.4 mg/kg weekly (up to 25 mg).
Croatian: Bolesnici su primali adalimumab u dozi od 0,8 mg/kg svaki drugi tjedan (do najviše 40 mg), 0,4 mg/kg svaki drugi tjedan (do najviše 20 mg) ili metotreksat u dozi od 0,1 - 0,4 mg/kg jednom tjedno (do najviše 25 mg).
English: Median time to disease flare
Croatian: Medijan vremena do reaktivacije bolesti
English: Note: P = Placebo (Number at Risk); H = Adalimumab (Number at Risk).
Croatian: Napomena: P = Placebo (broj bolesnika pod rizikom); H = adalimumab (broj bolesnika pod rizikom).
English: In these trials, 11.9% of patients treated with adalimumab and 8.1% of placebo and active control-treated patients that had negative baseline anti-nuclear antibody titres reported positive titres at week 24.
Croatian: U tim ispitivanjima, u 11,9% bolesnika liječenih adalimumabom i 8,1% bolesnika koji su primali placebo i aktivni kontrolni lijek i koji su prije početka liječenja imali negativan titar antinuklearnih protutijela zabilježen je pozitivan titar nakon 24 tjedna primjene lijeka.
English: 506 (62.2)b a Percent of patients achieving PASI75 response was calculated as centre-adjusted rate b p < 0.001, adalimumab versus placebo Table 18.
Croatian: 506 (62,2)b a Postotak bolesnika s rezultatom PASI 75 izražen kao stopa prilagođena istraživačkom centru b p < 0,001, adalimumab naspram placebo
English: Always hold the syringe by the syringe barrel.
Croatian: Uvijek držite štrcaljku za spremnik štrcaljke.
English: Physicians should exercise caution when considering the use of AMGEVITA in patients with a history of recurring infection or with underlying conditions which may predispose patients to infections, including the use of concomitant immunosuppressive medications.
Croatian: Liječnici trebaju oprezno razmotriti liječenje lijekom AMGEVITA u bolesnika s ponavljajućim infekcijama u anamnezi ili podležećim stanjima koja pogoduju razvoju infekcija u bolesnika, uključujući istodobnu primjenu imunosupresivnih lijekova.
English: No malignancies were observed in 249 paediatric patients with an exposure of 655.6 patient-years during adalimumab trials in patients with juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis).
Croatian: U 249 pedijatrijskih bolesnika s izloženošću od 655,6 bolesnik-godina tijekom ispitivanja adalimumaba u bolesnika s juvenilnim idiopatskim artritisom (poliartikularnim juvenilnim idiopatskim artritisom i artritisom povezanim s entezitisom) nisu primijećene zloćudne bolesti.
English: Mood alterations (including depression), Anxiety,
Croatian: Psihijatrijski poremećaji često promjene raspoloženja (uključujući depresiju), anksioznost, nesanica
English: 40 mg adalimumab every week
Croatian: 40 mg adalimumaba svaki tjedan
English: AMGEVITA is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).
Croatian: AMGEVITA je indicirana za liječenje umjerenog do teškog oblika aktivnog gnojnog hidradenitisa (acne inversa) u odraslih i adolescenata od 12 godina i starijih u kojih nije postignut zadovoljavajući odgovor na konvencionalno sistemsko liječenje gnojnog hidradenitisa (vidjeti dio 5.1 i 5.2).
English: Very common Respiratory tract infections (including lower and upper respiratory tract infection, pneumonia, sinusitis, pharyngitis, nasopharyngitis and pneumonia herpes viral)
Croatian: vrlo često infekcije dišnih putova (uključujući infekcije donjih i gornjih dišnih putova, pneumoniju, sinusitis, faringitis, nazofaringitis i pneumoniju uzrokovanu virusom herpesa)
English: During treatment with AMGEVITA, other concomitant therapies (e.g. corticosteroids and/or immunomodulatory agents) should be optimised.
Croatian: Tijekom liječenja lijekom AMGEVITA potrebno je prilagoditi ostalu istodobno primijenjenu terapiju (npr. kortikosteroide i/ili imunomodulirajuće lijekove).
English: ● Do not put the needle cap back onto the syringe.
Croatian: Nemojte vraćati zatvarač igle natrag naštrcaljku.
English: Placebo (treatment withdrawal) N = 73
Croatian: Placebo (ukidanje liječenja) N = 73
English: ● Do not recycle the pre-filled pen or sharps disposal container or throw them into the household waste.
Croatian: Nemojte reciklirati napunjenu brizgalicu niti spremnik za odlaganje oštrih predmeta ili ih bacati u kućni otpad.
English: At week 52, 42.9% of patients who received adalimumab/methotrexate combination therapy achieved clinical remission (DAS28 (CRP) < 2.6) compared to 20.6% of patients receiving methotrexate monotherapy and 23.4% of patients receiving adalimumab monotherapy.
Croatian: Nakon 52 tjedna liječenja, klinička remisija postignuta je u 42,9% bolesnika liječenih kombinacijom adalimumaba i metotreksata (DAS28 [CRP] < 2,6) u usporedbi s 20,6% bolesnika koji su dobivali monoterapiju metotreksatom, odnosno 23,4% bolesnika koji su dobivali monoterapiju adalimumabom.
English: L. Examine the injection site.
Croatian: Pregledajte mjesto injiciranja.
English: In patients with at least a partial response to adalimumab 40 mg weekly at week 12, the HiSCR rate at week 36 was higher in patients who continued weekly adalimumab than in patients in whom dosing frequency was reduced to every other week, or in whom treatment was withdrawn (see table 22).
Croatian: Među bolesnicima koji su u 12. tjednu ostvarili barem djelomičan odgovor na liječenje adalimumabom u dozi od 40 mg svaki tjedan, stopa HiSCR-a zabilježena u 36. tjednu bila je veća u onih bolesnika koji su nastavili primati adalimumab svaki tjedan nego u bolesnika kojima je učestalost doziranja smanjena na jednom svaki drugi tjedan ili onih kojima je liječenje ukinuto (vidjeti Tablicu 22).
English: Chest pain, Oedema, Pyrexia1)
Croatian: često bol u prsištu, edem, pireksija1)
English: ● Do not remove the finger flange.
Croatian: Ne uklanjajte hvatište za prste.
English: In the phase 3 trial of adalimumab in patients with paediatric Crohn's disease which evaluated efficacy and safety of two body weight adjusted maintenance dose regimens following body weight adjusted induction therapy up to 52 weeks of treatment, ALT elevations ≥ 3 x ULN occurred in 2.6% (5/192) of patients of whom 4 were receiving concomitant immunosuppressants at baseline.
Croatian: U ispitivanju faze III adalimumaba u pedijatrijskih bolesnika s Chronovom bolešću, koje je ocijenilo djelotvornost i sigurnost dvaju režima terapije održavanja dozom prilagođenom tjelesnoj težini nakon indukcijske terapije prilagođene tjelesnoj težini do 52 tjedna liječenja, povišenje ALT-a ≥ 3 x GGN javilo se u 2,6% (5/192) bolesnika, od kojih je njih četvero na početku liječenja bilo izloženo istodobnoj terapiji imunosupresivima.
English: When AMGEVITA therapy is initiated, a loading dose of 40 mg for patients < 30 kg or 80 mg for patients ≥ 30 kg may be administered one week prior to the start of maintenance therapy.
Croatian: Kad se uvodi liječenje lijekom AMGEVITA može se primijeniti udarna doza od 40 mg za bolesnike tjelesne težine < 30 kg ili 80 mg za bolesnike tjelesne težine ≥ 30 kg tjedan dana prije početka terapije održavanja.
English: Should treatment be interrupted, AMGEVITA 40 mg every week or 80 mg every other week may be re-introduced (see section 5.1).
Croatian: Ako liječenje treba privremeno prekinuti, AMGEVITA se kasnije može ponovno uvesti u dozi od 40 mg svaki tjedan ili 80 mg svaki drugi tjedan (vidjeti dio 5.1).
English: This medicine contains less than 1 mmol of sodium (23 mg) per 0.8 mL dose, i.e. essentially ‘sodiumfree'.
Croatian: Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po dozi od 0,8 ml, tj. zanemarive količine natrija.
English: AMGEVITA can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.
Croatian: AMGEVITA se može davati i kao monoterapija ako bolesnik ne podnosi metotreksat ili kada kontinuirana primjena metotreksata nije prikladna.
English: Pinch the skin firmly between your thumb and fingers, creating an area about 2 inch (5 centimetres) wide.
Croatian: Čvrsto uhvatite nabor kože između palca i ostalih prstiju, kako biste dobili oko 5 centimetara široko područje.
English: Of the patients who lost adequate response after re-randomisation to placebo who then enrolled into the openlabel extension trial, 38% (25/66) and 55% (36/66) regained PASI 75 response after 12 and 24 weeks of retreatment, respectively.
Croatian: Među bolesnicima u kojih je nastupio gubitak primjerenog odgovora nakon ponovne randomizacije u skupinu koja je primala placebo, a koji su potom uključeni u otvoreni produžetak ispitivanja, odgovor PASI 75 ponovno je postignut u 38% (25/66) bolesnika nakon 12 tjedana terapije, odnosno u 55% (36/66) bolesnika nakon 24 tjedna terapije.
English: The results for the 40 mg every other week dose are summarised in table 7.
Croatian: Rezultati zabilježeni u skupini koja je dobivala 40 mg svaka dva tjedna prikazani su u Tablici 7.
English: In an analysis in which all patients who dropped out of the study for adverse events or lack of efficacy, or who dose-escalated, were considered non-responders, PASI 75 and PGA of clear or minimal response rates in these patients were 69.6% and 55.7%, respectively, after an additional 108 weeks of open-label therapy (total of 160 weeks).
Croatian: U analizi u kojoj su se svi bolesnici koji su izašli iz ispitivanja zbog štetnih događaja ili nedostatka djelotvornosti ili kojima je doza povećavana smatrali bolesnicima bez odgovora na terapiju, stopa odgovora PASI 75 i PGA rezultata“bez bolesti” ili “minimalno” nakon dodatnih 108 tjedana otvorene terapije (ukupno 160 tjedana) iznosila je 69,6%, odnosno 55,7%.
English: AMGEVITA is administered every other week via subcutaneous injection.
Croatian: AMGEVITA se primijenjuje svaki drugi tjedan supkutanom injekcijom.
English: These trials included rheumatoid arthritis patients with short term and longstanding disease, juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and enthesitisrelated arthritis) as well as axial spondyloarthritis (ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of AS), psoriatic arthritis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa and uveitis patients.
Croatian: Ispitivanjima su obuhvaćeni bolesnici s nedavnom pojavom reumatoidnog artritisa i oni s dugotrajnom bolešću te bolesnici s juvenilnim idiopatskim artritisom (poliartikularnim juvenilnim idiopatskim artritisom i artritisom povezanim s entezitisom), kao i oni s aksijalnim spondiloartritisom (ankilozantnim spondilitisom i aksijalnim spondiloartritisom bez radiološkog dokaza AS-a), psorijatičnim artritisom, Crohnovom bolešću, ulceroznim kolitisom, psorijazom, gnojnim hidradenitisom i uveitisom.
English: Patients who were in the non-MTX stratum were either naïve to or had been withdrawn fromMTX at least two weeks prior to study drug administration.
Croatian: Bolesnici u ne-MTX skupini ili nikad nisu uzimali metotreksat ili su ga prestali uzimati bar dva tjedna prije uzimanja ispitivanog lijeka.
English: Medicine Make sure the medicine in the window is clear and colourless to slightly yellow.
Croatian: Provjerite da je lijek u prozorčiću bistar i bezbojan do blago žućkaste boje.
English: AMGEVITA slows down the damage to the cartilage and bone of the joints caused by the disease and to improve physical function.
Croatian: AMGEVITA usporava oštećenja hrskavičnih i koštanih zglobnih struktura uzrokovana bolešću i da poboljšava fizičku funkciju.
English: Eye infections,
Croatian: • infekcije oka,
English: ● The needle cover of the AMGEVITA pre-filled pen is made from dry natural rubber, which contains latex.
Croatian: Pokrov igle AMGEVITA napunjene brizgalice napravljen je od suhe prirodne gume koja sadrži lateks.
English: Each pack contains 1 single-use 20 mg pre-filled syringe (with yellow plunger rod).
Croatian: Svako pakiranje sadrži jednu napunjenu štrcaljku od 20 mg za jednokratnu primjenu (sa žutim klipom).